Salt Composition

Molnupiravir 200mg

You Searched

Movfor Capsule

Hetero Healthcare Ltd.

Bottle of 40 capsules

₹2,490

₹62.3 / Unit

All Our Medicines are

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)

Uses of Movfor Capsule

Treatment of Mild to moderate Coronavirus disease (COVID-19)

More About Movfor Capsule

Benefits

Side Effects

How to use

How it works

What if I forget to take it?

Manufacturer Address

Benefits

Treatment of Mild to moderate Coronavirus disease (COVID-19)

Side Effects

The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.

How to use

Follow your doctor's guidance regarding the dose and duration of this medication. Movfor Capsule can be taken it with or without food, although it's advisable to take it consistently at the same time.

How it works

Movfor Capsule is an antiviral medicine. It works by inhibiting the SARS-Co V-2 virus from replicating. This stops the virus from producing new copies and hence decreases the viral load in the body.

Alcohol

Consult your Doctor: Please consult your doctor regarding the safety of consuming alcohol with Movfor Capsule . Experts have not found evidence of alcohol impairing the effectiveness of the medicine.

Pregnancy

Seek medical advice from your doctor: Movfor Capsule may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.

Breast feeding

Not Safe: Movfor Capsule is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.

Driving

Seek medical advice from your doctor: It is not known whether Movfor Capsule alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.

Kidney

Safe when prescribed by an expert: Movfor Capsule is safe to use in patients with kidney disease. No dose adjustment of Movfor Capsule is recommended.

Liver

Safe when prescribed by an expert: Movfor Capsule is safe to use in patients with liver disease. No dose adjustment of Movfor Capsule is recommended.

What if I forget to take it?

If a dose of Movfor Capsule is missed, it's advisable to consult your doctor.

Manufacturer Address

S.no: 80-84, Melange towers, PatrikaNagar,Madhapur,Hyderabad. Telangana-500081.

Content Written By

Shubham Kumar Singh

B pharmacy

3 Years of Experience

Content Reviewed By

Dr. Jay Faldu

MBBS

7 Years of Experience

Checkout Editorial Policy

References

Molnupiravir (05 Jan. 2022)

U.S. Food and Drug Administration: Center for Drug Evaluation and Research FDA Briefing Document, Antimicrobial Drugs Advisory Committee Meeting, November 30, 2021 (05 Jan. 2022)

Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu®(Molnupiravir 200mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and with high risk of disease progression including hospitalization or death. Cipla: Press Statement (05 Jan. 2022)

Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India. Sun Pharma: Press Release (05 Jan. 2022)

Molnupiravir. U.S. Food & Drug Administration Antimicrobial Drugs Advisory Committee November 30, 2021 (05 Jan. 2022)

EUnetHTA Rolling Collaborative Review (RCR19) Authoring Team. Molnupiravir for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2020. Report No.: RCR19, v1.0 (05 Jan. 2022)

Molnupiravir (05 Jan. 2022)

European Medicines Agency. Assessment Report: Use of molnupiravir for the treatment of COVID-19 (05 Jan. 2022)

Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746 (05 Jan. 2022)

FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. December 23, 2021 (6th Jan. 2022)

Disclaimer

PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.